1. Academic Validation
  2. Protocol to co-culture SCLC cells with human CD8+ T cells to measure tumor cell killing and T cell activation

Protocol to co-culture SCLC cells with human CD8+ T cells to measure tumor cell killing and T cell activation

  • STAR Protoc. 2025 Jun 20;6(2):103767. doi: 10.1016/j.xpro.2025.103767.
Subhamoy Chakraborty 1 Subhasree Sridhar 2 Kedwin Ventura 1 Ramja Sritharan 1 Anna Tocheva 3 Triparna Sen 4
Affiliations

Affiliations

  • 1 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • 2 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • 3 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
  • 4 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: triparna.sen@mssm.edu.
Abstract

Small-cell lung Cancer (SCLC) is an aggressive malignancy with immunosuppressive tumor microenvironment limiting immunotherapy efficacy. Here, we present a protocol to assess T cell activation and the ability of lurbinectedin to enhance anti-tumor responses using in vitro co-cultures of SCLC cells and human CD8 T cells. We describe steps for cell seeding, treatment, co-culture setup, and assessing cell viability. This protocol provides a platform to study anti-tumor T cell responses and develop new SCLC therapies. For complete details on the use and execution of the protocol, please refer to Chakraborty et al.1.

Keywords

Cancer; Cell culture; Immunology; Molecular Biology.

Figures
Products